Category Archives: Funding

Vedanta Biosciences Closes Extended $45.5 Million Series C Financing

  May 13, 2019   $18.5 million in extension funding will support clinical pipeline of microbiome-derived product candidates CAMBRIDGE, Mass., May 13, 2019— Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, has raised an additional $18.5 million as an extension of its Series C […]

Pfizer Acquires Swiss Clinical-Stage Biotech Therachon

Expands Pfizer’s rare disease portfolio with potential first-in-class therapy for achondroplasia, a genetic condition and the most common form of short-limb dwarfism NEW YORK & BASEL, Switzerland–Pfizer (NYSE: PFE) today announced that it has entered into a definitive agreement to acquire all the shares of Therachon Holding AG, a privately-held clinical-stage biotechnology company focused on […]

Who is Switzerland’s Most Promising Startup 2019?

Switzerland is home to hundreds of excellent startups. Every year the TOP 100 Swiss Startup Award showcases the 100 most-innovative and promising Swiss startups. The event, a unique opportunity to discover the best of Swiss innovation, sees a jury of 100 leading investors and experts rank the country’s most-impactful new high-tech companies. You can vote […]

Forge And Basilea Enter Into Multi-Target Agreement To Discover And Develop Novel Antibiotics

San Diego, California, April 24, 2019 – Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea Pharmaceutica Ltd. [SIX: BSLN], announced today that they have entered into a research collaboration and license agreement to discover, develop, and commercialize novel antibiotic classes. They will apply Forge’s proprietary BLACKSMITH metalloenzyme chemistry […]

Polyneuron raises CHF 22.5 million in a major Series A financing

Leading venture capital firm Sofinnova Partners led the Series A financing, together with New Enterprise Associates, which co-led the round Basel, Switzerland, 28 March 2019 – Polyneuron Pharmaceuticals AG, a developer of a new class of biodegradable glycopolymers for the treatment of autoimmune diseases, today announced the closing of an oversubscribed CHF22.5 million Series A financing. […]

Cellestia Biotech raises CHF 20 million

Basel, 2018-12-19 – Cellestia Biotech AG successfully closes Series A financing round, raising a total of CHF 20 million. Melissa Kay Epstein elected to Board of Directors. Financing round led by FC Capital, Shanghai; PPF / Sotio, Prague; ETP Ventures, Boston & Beijing and significant investments by existing and new private investors Funds will be […]

Scailyte raises CHF 2.75M in seed funding and gains Swisscom Ventures & Zürcher Kantonalbank as investors

Scailyte AG, a Swiss startup in the emerging and rapidly growing field of single-cell technologies, raised CHF 2.75M in seed funding and gained Swisscom Ventures as a strategic investor. Zürcher Kantonalbank also joined the financing round, alongside the existing shareholders, thus reaffirming their trust in the competence and vision of Scailyte’s team. Dominique Megret, Head […]

Artidis: Cancer diagnosis in less than 3 hours

Marija Plodinec, CEO of Artidis (Img: Technologiepark Basel) “Artidis is based on the oldest diagnostic test on earth: palpation,” says Marija Plodinec, CEO and co-founder of Artidis AG. “In a nutshell, we palpate tissue on a molecular level,“ she adds with a twinkle. That’s because instead of a physician’s hand, Artidis runs a fine, high-precision […]

Resistell Closes Seed Round to Develop Faster Antibiotic Tests

Press release: Resistell AG closes seed round Resistell AG has today closed an oversubscribed seed financing round. Lead Investor Occident Group AG, Hemex AG and six other private investors invested in the EPFL spin-off developing the world’s fastest phenotypic antibiotic susceptibility test. 700,000 people die each year due to drug resistant infections. Unless we can […]